Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Deadline: The deadline for this grant has passed

Grant amount: Up to US $500,000

Funding uses: Research

Location of project: United States, American Samoa, Northern Mariana Islands, Puerto Rico, Virgin Islands

Location of residency: United States, American Samoa, Northern Mariana Islands, Puerto Rico, Virgin Islands

Overview:

NOTE: All applications are due by 5:00 PM local time of applicant organization. 

This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 

• development of in vitro and/or ex vivo assays that can support therapeutic screening efforts,
• screening efforts to identify and characterize potential therapeutic agents, and
• therapeutic optimization, pharmacodynamic and pharmacokinetic studies.

The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.